SMShabir A. Madhi

Shabir A. Madhi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shabir A. Madhi has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Keith P. Klugman

    Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand/Medical Research Council, and

    10 shared publications
  • Clare L. Cutland

    Wits African Leadership in Vaccinology Expertise (Wits-Alive), School of Pathology, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa

    9 shared publications
  • Locadiah Kuwanda

    Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand/Medical Research Council, and

    9 shared publications
  • Nadia van Niekerk

    3 shared publications
  • Helena Käyhty

    Hubert Department of Global Health, Rollins School of Public Health and Division of Infectious Diseases, School of Medicine, Emory University, Atlanta, Georgia

    2 shared publications
  • Herbert Ludewick

    2 shared publications

Latest Publications

  • Open Access

    Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis

    by Brigitte Cheuvart, Kathleen M Neuzil, A Duncan Steele, Nigel Cunliffe, Shabir A Madhi, Naveen Karkada, Htay Htay Han, Carla Vinals

    Clinical trials of the human rotavirus vaccine Rotarix™ (RV1) have demonstrated significant reductions in severe rotavirus gastroenteritis (RVGE) in children worldwide. However, no correlate of vaccine efficacy (VE) has yet been established. This paper presents 2 analyses which aimed to investigate whether serum anti-RV IgA measured by ELISA 1 or 2 mo post-vaccination can serve as a correlate of efficacy against RVGE: (1) In a large Phase III efficacy trial (Rota-037), the Prentice criteria for surrogate endpoints was applied to anti-RV IgA seropositivity 1 mo post-vaccination. These criteria determine whether a significant vaccine group effect can be predicted from the surrogate, namely seropositivity (anti-RV IgA concentration >20 U/mL); (2) Among other GSK-sponsored RV1 VE studies, 8 studies which assessed immunogenicity at 1 or 2 mo post-vaccination in all or a sub-cohort of enrolled subjects and had at least 10 RVGE episodes were included in a meta-analysis to measure the regression between clinical VE and VE predicted from immunogenicity (VE1). In Rota-037, anti-RV IgA seropositivity post-vaccination was associated with a lower incidence of any or severe RVGE, however, the proportion of vaccine group effect explained by seropositivity was only 43.6% and 32.7% respectively. This low proportion was due to the vaccine group effect observed in seronegative subjects. In the meta-analysis, the slope of the regression between clinical VE and VE1 was statistically significant. These two independent analyses support the hypothesis that post-vaccination anti-RV IgA seropositivity (antibody concentration ≥20 U/mL) may serve as a useful correlate of efficacy in clinical trials of RV1 vaccines.


  • Open Access

    An evaluation of emerging vaccines for childhood pneumococcal pneumonia

    by Julia Webster, Evropi Theodoratou, Harish Nair, Ang Choon Seong, Lina Zgaga, Tanvir Huda, Hope L Johnson, Shabir Madhi, Craig Rubens, Jian Shayne F Zhang, et al.

    Background: Pneumonia is the leading cause of child mortality worldwide. Streptococcus pneumoniae (SP) or pneumococcus is estimated to cause 821,000 child deaths each year. It has over 90 serotypes, of which 7 to 13 serotypes are included in current formulations of pneumococcal conjugate vaccines that are efficacious in young children. To further reduce the burden from SP pneumonia, a vaccine is required that could protect children from a greater diversity of serotypes. Two different types of vaccines against pneumococcal pneumonia are currently at varying stages of development: a multivalent pneumococcal conjugate vaccine covering additional SP serotypes; and a conserved common pneumococcal protein antigen (PPA) vaccine offering protection for all serotypes. Methods: We used a modified CHNRI methodology for setting priorities in health research investments. This was done in two stages. In Stage I, we systematically reviewed the literature related to emerging SP vaccines relevant to several criteria of interest: answerability; efficacy and effectiveness; cost of development, production and implementation; deliverability, affordability and sustainability; maximum potential for disease burden reduction; acceptability to the end users and health workers; and effect on equity. In Stage II, we conducted an expert opinion exercise by inviting 20 experts (leading basic scientists, international public health researchers, international policy makers and representatives of pharmaceutical companies). The policy makers and industry representatives accepted our invitation on the condition of anonymity, due to sensitive nature of their involvement in such exercises. They answered questions from CHNRI framework and their “collective optimism” towards each criterion was documented on a scale from 0 to 100%. Results: The experts expressed very high level of optimism (over 80%) that low-cost polysaccharide conjugate SP vaccines would satisfy each of the 9 relevant CHNRI criteria. The median potential effectiveness of conjugate SP vaccines in reduction of overall childhood pneumonia mortality was predicted to be about 25% (interquartile range 20-38%, min. 15%, max 45%). For low cost, cross-protective common protein vaccines for SP the experts expressed concerns over answerability (72%) and the level of development costs (50%), while the scores for all other criteria were over 80%. The median potential effectiveness of common protein vaccines in reduction of overall childhood pneumonia mortality was predicted to be about 30% (interquartile range 26-40%, min. 20%, max 45%). Conclusions: Improved SP vaccines are a very promising investment that could substantially contribute to reduction of child mortality world-wide.


  • Open Access

    Quantitative and Qualitative Anamnestic Immune Responses to Pneumococcal Conjugate Vaccine in HIV‐Infected and HIV‐Uninfected Children 5 Years after Vaccination

    by Shabir A. Madhi, Keith P. Klugman, Locadiah Kuwanda, Clare Cutland, Helena Käyhty, Peter Adrian

    BackgroundAdministration of pneumococcal conjugate vaccine (PCV) to HIV-infected children during infancy confers limited long-term protection in the


  • Interaction between influenza virus andStreptococcus pneumoniaein severe pneumonia

    by Shabir A Madhi, Barry Schoub, Keith P Klugman

    The contribution of bacterial superinfection to influenza-associated pneumonia morbidity and mortality is evident from the 1918 and 1957 influenza pandemics, and is supported by a number of murine model studies. Murine model studies have also assisted in helping to expand our understanding of the pathogenesis of the interaction between the influenza virus and subsequent susceptibility to pneumococcal superinfections. The purported impact that the pneumococcal conjugate vaccine has had on reducing the burden of confirmed influenza-associated pneumonia, as well as upon all-cause clinical pneumonia, provides additional clinical evidence of the role of superimposed pneumococcal infections as a cause of severe pneumonia in children. Using this information together with the evidence for the effectiveness of influenza vaccination against influenza-associated pneumonia, it is imperative that preventive strategies for future influenza pandemic preparedness include broad-based vaccination against pneumococci, as well as ensuring that adequate antimicrobials are available for the early treatment of influenza virus, in addition to pneumococcal and other bacterial infections.


  • Vaccines to prevent pneumonia and improve child survival

    by Shabir Madhi

    For more than 30 years, vaccines have played an important part in pneumonia prevention. Recent advances have created opportunities for further improving child survival through prevention of childhood pneumonia by vaccination. Maximizing routine immunization with pertussis and measles vaccines, coupled with provision of a second opportunity for measles immunization, has rapidly reduced childhood deaths in low-income countries especially in sub-Saharan Africa.


  • Open Access

    Introduction of the pneumococcal conjugate vaccine into the South African public immunisation programme: dawn of a new era?

    by S.A. Madhi

    Streptococcus pneumoniae is a leading vaccine-preventable cause of childhood death with an estimated 716,000 deaths occurring annually. Recent advances have seen the development of vaccines targeted against S. pneumoniae that are immunogenic and effcacious in very young children. These pneumococcal conjugate vaccines have now been evaluated in developed and industrialising countries with consistent effcacy against invasive pneumococcal disease at least due to the serotypes included in the vaccine. The vaccine has also been effcacious in preventing radiographically confrmed pneumonia, but has had less effect on pneumococcal acute otitis media. The introduction of the vaccine into the USA has been greatly successful and exceeds its expectations based upon the vaccine effcacy trials. In addition to preventing a greater than expected burden of invasive disease and pneumonia than anticipated in vaccinated children, the vaccine has also been associated with marked reduction in pneumococcal disease among unvaccinated members of the population, referred to as 'indirect protection'. The introduction of the vaccine into the immunisation programme of industrialising countries, such as in South Africa, require robust surveillance to evaluate the effectiveness of the vaccine in such settings where the epidemiology of pneumococcal diseases differs to that in developed countries.


  • Long‐Term Effect of Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization byStreptococcus pneumoniae—and Associated Interactions withStaphylococcus aureusandHaemophilus influenzaeColonization—in HIV‐Infected and HIV‐Uninfected Children

    by Shabir A. Madhi, Peter Adrian, Locadiah Kuwanda, Clare Cutland, Werner C. Albrich, Keith P. Klugman

    After a primary series of 3 doses, it was found that a 9-valent pneumococcal conjugate vaccine no longer reduces nasopharyngeal colonization by vaccine serotypes in childern 5.3 years of age. In addition, human immunodeficiency virus (HIV-infected children (n= 81) had a higher prevalence of colonization by Streptococcus pneumoniae and Haemophilus influenzae (71.6% and 74.1%, respectively) than did HIV-uninfected children (n = 271; 50.9% and 52.0%, respectively), suggesting that increased colonization may contribute to the greater burden of pneumococcal disease in HIV-infected children. Inverse associations between colonization by S. pneumoniae and colonization by Staphylococcus aureus and between colonization by S. aureus and colonization by H. influenzae were observed only in HIV-uninfected children, possibly as a result of suboptimal adaptive immunity after previous colonization in HIV-infected children.


  • Seasonality, Incidence, and Repeat Human Metapneumovirus Lower Respiratory Tract Infections in an Area With a High Prevalence of Human Immunodeficiency Virus Type-1 Infection

    by Shabir A. Madhi, Herbert Ludewick, Locadiah Kuwanda, Nadia van Niekerk, Clare Cutland, Keith P. Klugman

    There is limited information regarding the epidemiology of human metapneumovirus (hMPV) from Africa, despite it being identified as a common pathogen in children with pneumonia. Determine the epidemiology of severe hMPV-associated lower respiratory tract infection (LRTI) in human immunodeficiency virus type-1 (HIV) infected and uninfected children. Nasopharyngeal aspirate samples from children hospitalized for LRTI between January 2000 and December 2002 were analyzed for common respiratory viruses using an immunofluorescence assay; and 2715 available nasopharyngeal aspirate samples were tested for hMPV by reverse-transcriptase polymerase chain reaction targeting its fusion protein. Phylogenetic analysis of the fusion (F) gene was performed on samples associated with repeat hMPV infections in the same child. hMPV was identified perennially and was the second most commonly identified respiratory virus (11.3% versus 21.1% for respiratory syncytial virus, P < 0.0001) in HIV-uninfected children. The burden of hospitalization for hMPV-LRTI was 5.4 (95% CI: 3.5-7.5) fold greater in HIV-infected (2935 per 100,000) compared with HIV-uninfected children [575 (95% CI: 472-695) per 100,000]. HIV-infected children had greater evidence of bacterial coinfection and a higher mortality rate than did uninfected children. Repeat hMPV associated hospitalizations involved homologous (B2 subgroup) and heterologous (A1 and B2) hMPV. There is a high burden of hMPV-LRTI and repeat severe infections occur from homologous and heterologous subgroups of the virus.